scPharmaceuticals (SCPH) Gets a Buy from SVB Securities

In a report released on November 28, Roanna Ruiz from SVB Securities reiterated a Buy rating on scPharmaceuticals (SCPHResearch Report), with a price target of $12.00. The company’s shares closed yesterday at $7.20.

Ruiz covers the Healthcare sector, focusing on stocks such as scPharmaceuticals, Lantheus, and Enanta Pharmaceuticals. According to TipRanks, Ruiz has an average return of -43.9% and a 12.00% success rate on recommended stocks.

Currently, the analyst consensus on scPharmaceuticals is a Strong Buy with an average price target of $14.25.

See the top stocks recommended by analysts >>

Based on scPharmaceuticals’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $10.16 million. In comparison, last year the company had a GAAP net loss of $6.55 million

Based on the recent corporate insider activity of 7 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of SCPH in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

scPharmaceuticals, Inc.engages in the development of transformative pharmaceutical products for subcutaneous delivery. Its products include furosemide, used as parenteral diuretic in treating heart failure and ceftriaxone, used as parenteral antibiotic outside the hospital setting. The company was founded by Pieter Muntendam and Bertram Pitt in February 2013 and is headquartered in Burlington, MA.

Read More on SCPH:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More